PURPOSE: Intensive postoperative surveillance is associated with improved survival and recommended for patients with late stage (stage IIB and III) colon cancer. We hypothesized that stage I and IIA colon cancer patients would experience similar benefits. PATIENTS AND METHODS: Secondary analysis of data from the Clinical Outcomes of Surgical Therapy trial was performed by analyzing results according to TNM stage; early (stage I and IIA, 537 patients) and late (stage IIB and III, 254 patients) stage disease. Five-year recurrence rates were higher in patients with late (35.7%) versus early stage disease (9.5%). Early and late stage salvage rates, recurrence patterns and methods of first detection were compared by chi(2) test. RESULTS:Salvage rates for early- and late-stage disease patients with recurrence were the same (35.9% v 37%; P = .9, respectively). Median survival after second surgery after recurrence was 51.2 and 35.8 months for early- and late-stage patients, respectively. Single sites of first recurrence did not significantly differ between early and late stage, but multiple sites of recurrence occurred less often in early-stage patients (3.6% v 28.6%, for early v late, respectively; P < .001). METHODS of first detection of recurrence were not significantly different: carcinoembryonic antigen (29.1% v 37.4%), computed tomography scan (23.6% v 26.4%), chest x-ray (7.3% v 12.1%), and colonoscopy (12.7% v 8.8%), for early versus late stage disease, respectively. CONCLUSION:Patients with early-stage colon cancer have similar sites of recurrence, and receive similar benefit from postrecurrence therapy as late-stage patients; implementation of surveillance guidelines for early-stage patients is appropriate.
RCT Entities:
PURPOSE: Intensive postoperative surveillance is associated with improved survival and recommended for patients with late stage (stage IIB and III) colon cancer. We hypothesized that stage I and IIA colon cancerpatients would experience similar benefits. PATIENTS AND METHODS: Secondary analysis of data from the Clinical Outcomes of Surgical Therapy trial was performed by analyzing results according to TNM stage; early (stage I and IIA, 537 patients) and late (stage IIB and III, 254 patients) stage disease. Five-year recurrence rates were higher in patients with late (35.7%) versus early stage disease (9.5%). Early and late stage salvage rates, recurrence patterns and methods of first detection were compared by chi(2) test. RESULTS: Salvage rates for early- and late-stage diseasepatients with recurrence were the same (35.9% v 37%; P = .9, respectively). Median survival after second surgery after recurrence was 51.2 and 35.8 months for early- and late-stage patients, respectively. Single sites of first recurrence did not significantly differ between early and late stage, but multiple sites of recurrence occurred less often in early-stage patients (3.6% v 28.6%, for early v late, respectively; P < .001). METHODS of first detection of recurrence were not significantly different: carcinoembryonic antigen (29.1% v 37.4%), computed tomography scan (23.6% v 26.4%), chest x-ray (7.3% v 12.1%), and colonoscopy (12.7% v 8.8%), for early versus late stage disease, respectively. CONCLUSION:Patients with early-stage colon cancer have similar sites of recurrence, and receive similar benefit from postrecurrence therapy as late-stage patients; implementation of surveillance guidelines for early-stage patients is appropriate.
Authors: Thomas Anthony; Clifford Simmang; Neil Hyman; Donald Buie; Donald Kim; Peter Cataldo; Charles Orsay; James Church; Daniel Otchy; Jeffery Cohen; W Brian Perry; Gary Dunn; Janice Rafferty; C Neal Ellis; Jan Rakinic; Phillip Fleshner; Thomas Stahl; Sharon Gregorcyk; Charles Ternent; John W Kilkenny; Mark Whiteford Journal: Dis Colon Rectum Date: 2004-05-04 Impact factor: 4.585
Authors: Felix G Fernandez; Jeffrey A Drebin; David C Linehan; Farrokh Dehdashti; Barry A Siegel; Steven M Strasberg Journal: Ann Surg Date: 2004-09 Impact factor: 12.969
Authors: Mace L Rothenberg; Amit M Oza; Robert H Bigelow; Jordan D Berlin; John L Marshall; Ramesh K Ramanathan; Lowell L Hart; Sunil Gupta; Carlos A Garay; Brent G Burger; Nathalie Le Bail; Daniel G Haller Journal: J Clin Oncol Date: 2003-06-01 Impact factor: 44.544
Authors: J F Regnard; D Grunenwald; L Spaggiari; P Girard; D Elias; M Ducreux; P Baldeyrou; P Levasseur Journal: Ann Thorac Surg Date: 1998-07 Impact factor: 4.330
Authors: Eddie K Abdalla; Jean-Nicolas Vauthey; Lee M Ellis; Vickie Ellis; Raphael Pollock; Kristine R Broglio; Kenneth Hess; Steven A Curley Journal: Ann Surg Date: 2004-06 Impact factor: 12.969
Authors: Cindy Zer; Kendra N Avery; Kassondra Meyer; Leah Goodstein; Krzysztof P Bzymek; Gagandeep Singh; John C Williams Journal: Protein Eng Des Sel Date: 2017-06-01 Impact factor: 1.650
Authors: Ryan P Merkow; Deborah Korenstein; Rubaya Yeahia; Peter B Bach; Shrujal S Baxi Journal: JAMA Intern Med Date: 2017-05-01 Impact factor: 21.873
Authors: Melissa K Accordino; Jason D Wright; Sowmya Vasan; Alfred I Neugut; Ana Tergas; Jim C Hu; Dawn L Hershman; Melissa K Accordino; Jason D Wright; Sowmya Vasan; Alfred I Neugut; Ana Tergas; Jim C Hu; Dawn L Hershman Journal: J Oncol Pract Date: 2015-09-15 Impact factor: 3.840
Authors: Enikő Orosz; István Ember; Katalin Gombos; László Tóth; Ádám Tarpay; Ákos Pap; Szabolcs Ottó Journal: Pathol Oncol Res Date: 2013-07-19 Impact factor: 3.201
Authors: L Chen; B Jiang; Z Wang; M Liu; H Yang; J Xing; C Zhang; Z Yao; N Zhang; M Cui; X Su Journal: Clin Transl Oncol Date: 2013-07-17 Impact factor: 3.405